Krsnaa Diagnostics Reports 10.5% Revenue Growth in Q2 FY2025-26

Krsnaa Diagnostics Limited (NSE: KRSNAA) has reported a strong financial performance for the second quarter of the fiscal year 2025-26, showcasing significant growth across key metrics.

Financial Highlights

The company's consolidated financial results for Q2 FY2025-26 reveal year-over-year improvements:

Metric (in million rupees)	Q2 FY2025-26	Q2 FY2024-25	YoY Growth
Revenue from Operations	2,059.91	1,863.40	10.5%
EBITDA	592.39	494.00	19.9%
Net Profit	239.45	195.96	22.2%
EBITDA Margin	28.74%	26.52%	222 bps

Revenue Growth and Operational Performance

Krsnaa Diagnostics witnessed a 10.5% year-over-year increase in revenue from operations, reaching 2,059.91 million rupees in Q2 FY2025-26.

Profitability Improvements

The company's financial results show:

EBITDA grew by 19.9% to 592.39 million rupees.
Net profit increased by 22.2%, reaching 239.45 million rupees.
The EBITDA margin expanded by 222 basis points to 28.74%.

Balance Sheet and Cash Flow

As of September 30, 2025, Krsnaa Diagnostics reported:

Total assets of 15,066.91 million rupees
Total equity of 9,229.55 million rupees
Cash and cash equivalents of 105.60 million rupees

The company's cash flow from operating activities for the half-year ended September 30, 2025, stood at 518.74 million rupees.

Outlook

The diagnostic services sector in India continues to show growth potential. Krsnaa Diagnostics' performance in Q2 FY2025-26 reflects positively on its position in the market.

Note: This article is based on the consolidated financial results of Krsnaa Diagnostics Limited for the quarter ended September 30, 2025. Investors are advised to review the full financial statements and consult with financial advisors before making investment decisions.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-0.52%	-0.71%	+1.90%	+26.47%	-19.05%	-17.86%

Krsnaa Diagnostics Limited, a leading provider of diagnostic services in India, has reported a strong performance for the first quarter, along with a significant new contract win in Rajasthan.

Financial Highlights

Krsnaa Diagnostics achieved a revenue of INR 1,930.00 million in Q1, marking a 13% year-over-year growth. The company's EBITDA stood at INR 524.00 million with a 27% margin, while Profit After Tax (PAT) reached INR 205.00 million, representing an 11% margin. Earnings Per Share (EPS) increased by 14% to INR 6.25 from INR 5.46 in the same quarter last year.

Operational Performance

During the quarter, Krsnaa served 5 million patients and processed 16 million tests. The company's retail touchpoints expanded significantly from 362 to 2,414 year-over-year, now contributing 6% of group revenues.

Rajasthan PPP Contract

In a major development, Krsnaa Diagnostics won a substantial Public-Private Partnership (PPP) contract in Rajasthan. The project involves setting up:

42 mother labs
135 satellite labs
Over 1,300 collection centers

This contract is expected to generate INR 300.00-350.00 crores in annualized revenue once fully operational. The company plans to invest INR 200.00-250.00 crores in this project, with implementation expected to be completed within 6-9 months.

Expansion and Future Outlook

Krsnaa added 3 labs, 2 CT scanners, and 3 MRI machines in Q1, further expanding its diagnostic capabilities. The company's management expects the retail business to reach EBITDA breakeven by the end of FY26 and aims for it to contribute 5-8% of total revenue by FY26, with a target of 18-20% contribution within two years.

Management Commentary

Yash Mutha, Managing Director of Krsnaa Diagnostics, commented on the results: "Our Q1 performance demonstrates scale with profitability. We are uniquely positioned to lead the growth in the diagnostics sector, operating across 18 states and union territories, delivering integrated radiology, pathology, and teleradiology services."

Regarding the Rajasthan contract, Mutha added, "This is a transformative achievement for us, significantly expanding our presence in pathology services across Rajasthan. We expect material revenues to start flowing from FY27 onwards."

Conclusion

Krsnaa Diagnostics continues to strengthen its position in the Indian diagnostics market through its hybrid model of PPP and retail operations. With its focus on affordable, high-quality diagnostics and strategic expansion plans, the company is well-positioned for sustained growth in the coming years.